Global Dilated Cardiomyopathy Therapeutic Market

Dilated Cardiomyopathy Therapeutic Comprehensive Study by Drug Class (Aldosterone antagonists, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers, Beta-blockers, Others), End User (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028

Dilated Cardiomyopathy Therapeutic Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dilated Cardiomyopathy Therapeutic
Dilated cardiomyopathy is a significant cause of heart failure and a leading indication for heart transplants among children and adults across the globe. This condition is characterized by enlargement of the ventricular chamber, thinning of heart walls, and inability to sufficiently pump blood throughout the body. Dilated cardiomyopathy can develop at any age but is more common among people aged between 20 years to 60 years. Genetic inheritance is found to affect about 30% to 40% of the total DCM patients. This has led to significant growth of the global dilated cardiomyopathy therapeutics market in the forecast period.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that European and United States Players will contribute the maximum growth to Global Dilated Cardiomyopathy Therapeutic market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Zensun Shanghai Sci & Tech Co Ltd (China), Capricor Therapeutics, Inc.(United States), Vericel Corporation (United States), AstraZeneca plc. (United Kingdom), Pfizer Inc. (United States), t2cure GmbH (Germany), MyoKardia (United States), Janssen Pharmaceuticals, Inc. (Belgium), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel) and Vericel Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Array BioPharma, Inc.(United States), Celladon Corporation (United States) and GlaxoSmithKline plc. (United Kingdom).

Segmentation Overview
AMA Research has segmented the market of Global Dilated Cardiomyopathy Therapeutic market by and Region.



On the basis of geography, the market of Dilated Cardiomyopathy Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Class, the sub-segment i.e. Aldosterone antagonists will boost the Dilated Cardiomyopathy Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Dilated Cardiomyopathy Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Incidence of Cardiovascular Diseases

Market Growth Drivers:
Rising Incidences of Congestive Heart Failure across the Globe and Increasing Number of People Suffering from Cardiac Muscle Infections, along with the Drug or Alcohol Abuse

Challenges:
High Cost Associated with Dilated Cardiomyopathy Therapeutic

Restraints:
Whereas the Side Effects of Dilated Cardiomyopathy Therapeutic

Opportunities:
Technological Advancement and Development in Dilated Cardiomyopathy Therapeutic

Market Leaders and their expansionary development strategies
In September 2023, Verily and Medtronic this strategic partnership focuses on advancing research and development in cardiovascular health, with potential applications for DCM diagnosis and treatment through AI and big data analysis.
In October 2023, Phase IIb trial Encouraging results from a Phase IIb clinical trial testing a gene therapy approach for DCM treatment were reported. This gene therapy targets a specific mutation linked to DCM and aims to improve heart function.


Key Target Audience
Dilated Cardiomyopathy Therapeutic Providers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drug Class
  • Aldosterone antagonists
  • Angiotensin-converting enzyme (ACE) Inhibitors
  • Angiotensin II Receptor Blockers
  • Beta-blockers
  • Others

By End User
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidences of Congestive Heart Failure across the Globe
      • 3.2.2. Increasing Number of People Suffering from Cardiac Muscle Infections, along with the Drug or Alcohol Abuse
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated with Dilated Cardiomyopathy Therapeutic
    • 3.4. Market Trends
      • 3.4.1. Rising Incidence of Cardiovascular Diseases
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dilated Cardiomyopathy Therapeutic, by Drug Class, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dilated Cardiomyopathy Therapeutic (Value)
      • 5.2.1. Global Dilated Cardiomyopathy Therapeutic by: Drug Class (Value)
        • 5.2.1.1. Aldosterone antagonists
        • 5.2.1.2. Angiotensin-converting enzyme (ACE) Inhibitors
        • 5.2.1.3. Angiotensin II Receptor Blockers
        • 5.2.1.4. Beta-blockers
        • 5.2.1.5. Others
      • 5.2.2. Global Dilated Cardiomyopathy Therapeutic by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Dilated Cardiomyopathy Therapeutic Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Dilated Cardiomyopathy Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Zensun Shanghai Sci & Tech Co Ltd (China)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Capricor Therapeutics, Inc.(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Vericel Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. T2cure GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MyoKardia (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis International AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Vericel Corporation (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Dilated Cardiomyopathy Therapeutic Sale, by Drug Class, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dilated Cardiomyopathy Therapeutic (Value)
      • 7.2.1. Global Dilated Cardiomyopathy Therapeutic by: Drug Class (Value)
        • 7.2.1.1. Aldosterone antagonists
        • 7.2.1.2. Angiotensin-converting enzyme (ACE) Inhibitors
        • 7.2.1.3. Angiotensin II Receptor Blockers
        • 7.2.1.4. Beta-blockers
        • 7.2.1.5. Others
      • 7.2.2. Global Dilated Cardiomyopathy Therapeutic by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Dilated Cardiomyopathy Therapeutic Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dilated Cardiomyopathy Therapeutic: by Drug Class(USD Million)
  • Table 2. Dilated Cardiomyopathy Therapeutic Aldosterone antagonists , by Region USD Million (2017-2022)
  • Table 3. Dilated Cardiomyopathy Therapeutic Angiotensin-converting enzyme (ACE) Inhibitors , by Region USD Million (2017-2022)
  • Table 4. Dilated Cardiomyopathy Therapeutic Angiotensin II Receptor Blockers , by Region USD Million (2017-2022)
  • Table 5. Dilated Cardiomyopathy Therapeutic Beta-blockers , by Region USD Million (2017-2022)
  • Table 6. Dilated Cardiomyopathy Therapeutic Others , by Region USD Million (2017-2022)
  • Table 7. Dilated Cardiomyopathy Therapeutic: by End User(USD Million)
  • Table 8. Dilated Cardiomyopathy Therapeutic Hospitals , by Region USD Million (2017-2022)
  • Table 9. Dilated Cardiomyopathy Therapeutic Clinics , by Region USD Million (2017-2022)
  • Table 10. Dilated Cardiomyopathy Therapeutic Others , by Region USD Million (2017-2022)
  • Table 11. South America Dilated Cardiomyopathy Therapeutic, by Country USD Million (2017-2022)
  • Table 12. South America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 13. South America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 14. Brazil Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 15. Brazil Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 16. Argentina Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 17. Argentina Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 18. Rest of South America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 19. Rest of South America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 20. Asia Pacific Dilated Cardiomyopathy Therapeutic, by Country USD Million (2017-2022)
  • Table 21. Asia Pacific Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 22. Asia Pacific Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 23. China Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 24. China Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 25. Japan Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 26. Japan Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 27. India Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 28. India Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 29. South Korea Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 30. South Korea Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 31. Taiwan Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 32. Taiwan Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 33. Australia Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 34. Australia Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 36. Rest of Asia-Pacific Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 37. Europe Dilated Cardiomyopathy Therapeutic, by Country USD Million (2017-2022)
  • Table 38. Europe Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 39. Europe Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 40. Germany Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 41. Germany Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 42. France Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 43. France Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 44. Italy Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 45. Italy Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 46. United Kingdom Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 47. United Kingdom Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 48. Netherlands Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 49. Netherlands Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 50. Rest of Europe Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 51. Rest of Europe Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 52. MEA Dilated Cardiomyopathy Therapeutic, by Country USD Million (2017-2022)
  • Table 53. MEA Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 54. MEA Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 55. Middle East Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 56. Middle East Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 57. Africa Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 58. Africa Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 59. North America Dilated Cardiomyopathy Therapeutic, by Country USD Million (2017-2022)
  • Table 60. North America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 61. North America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 62. United States Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 63. United States Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 64. Canada Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 65. Canada Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 66. Mexico Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2017-2022)
  • Table 67. Mexico Dilated Cardiomyopathy Therapeutic, by End User USD Million (2017-2022)
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Dilated Cardiomyopathy Therapeutic: by Drug Class(USD Million)
  • Table 81. Dilated Cardiomyopathy Therapeutic Aldosterone antagonists , by Region USD Million (2023-2028)
  • Table 82. Dilated Cardiomyopathy Therapeutic Angiotensin-converting enzyme (ACE) Inhibitors , by Region USD Million (2023-2028)
  • Table 83. Dilated Cardiomyopathy Therapeutic Angiotensin II Receptor Blockers , by Region USD Million (2023-2028)
  • Table 84. Dilated Cardiomyopathy Therapeutic Beta-blockers , by Region USD Million (2023-2028)
  • Table 85. Dilated Cardiomyopathy Therapeutic Others , by Region USD Million (2023-2028)
  • Table 86. Dilated Cardiomyopathy Therapeutic: by End User(USD Million)
  • Table 87. Dilated Cardiomyopathy Therapeutic Hospitals , by Region USD Million (2023-2028)
  • Table 88. Dilated Cardiomyopathy Therapeutic Clinics , by Region USD Million (2023-2028)
  • Table 89. Dilated Cardiomyopathy Therapeutic Others , by Region USD Million (2023-2028)
  • Table 90. South America Dilated Cardiomyopathy Therapeutic, by Country USD Million (2023-2028)
  • Table 91. South America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 92. South America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 93. Brazil Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 94. Brazil Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 95. Argentina Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 96. Argentina Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 97. Rest of South America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 98. Rest of South America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 99. Asia Pacific Dilated Cardiomyopathy Therapeutic, by Country USD Million (2023-2028)
  • Table 100. Asia Pacific Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 101. Asia Pacific Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 102. China Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 103. China Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 104. Japan Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 105. Japan Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 106. India Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 107. India Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 108. South Korea Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 109. South Korea Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 110. Taiwan Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 111. Taiwan Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 112. Australia Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 113. Australia Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 114. Rest of Asia-Pacific Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 115. Rest of Asia-Pacific Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 116. Europe Dilated Cardiomyopathy Therapeutic, by Country USD Million (2023-2028)
  • Table 117. Europe Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 118. Europe Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 119. Germany Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 120. Germany Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 121. France Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 122. France Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 123. Italy Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 124. Italy Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 125. United Kingdom Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 126. United Kingdom Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 127. Netherlands Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 128. Netherlands Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 129. Rest of Europe Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 130. Rest of Europe Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 131. MEA Dilated Cardiomyopathy Therapeutic, by Country USD Million (2023-2028)
  • Table 132. MEA Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 133. MEA Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 134. Middle East Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 135. Middle East Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 136. Africa Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 137. Africa Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 138. North America Dilated Cardiomyopathy Therapeutic, by Country USD Million (2023-2028)
  • Table 139. North America Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 140. North America Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 141. United States Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 142. United States Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 143. Canada Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 144. Canada Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 145. Mexico Dilated Cardiomyopathy Therapeutic, by Drug Class USD Million (2023-2028)
  • Table 146. Mexico Dilated Cardiomyopathy Therapeutic, by End User USD Million (2023-2028)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dilated Cardiomyopathy Therapeutic: by Drug Class USD Million (2017-2022)
  • Figure 5. Global Dilated Cardiomyopathy Therapeutic: by End User USD Million (2017-2022)
  • Figure 6. South America Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 7. Asia Pacific Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 8. Europe Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 9. MEA Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 10. North America Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 11. Global Dilated Cardiomyopathy Therapeutic share by Players 2022 (%)
  • Figure 12. Global Dilated Cardiomyopathy Therapeutic share by Players (Top 3) 2022(%)
  • Figure 13. Global Dilated Cardiomyopathy Therapeutic share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Zensun Shanghai Sci & Tech Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 16. Zensun Shanghai Sci & Tech Co Ltd (China) Revenue: by Geography 2022
  • Figure 17. Capricor Therapeutics, Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 18. Capricor Therapeutics, Inc.(United States) Revenue: by Geography 2022
  • Figure 19. Vericel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Vericel Corporation (United States) Revenue: by Geography 2022
  • Figure 21. AstraZeneca plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 25. T2cure GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. T2cure GmbH (Germany) Revenue: by Geography 2022
  • Figure 27. MyoKardia (United States) Revenue, Net Income and Gross profit
  • Figure 28. MyoKardia (United States) Revenue: by Geography 2022
  • Figure 29. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 30. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2022
  • Figure 31. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 33. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 35. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2022
  • Figure 37. Vericel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Vericel Corporation (United States) Revenue: by Geography 2022
  • Figure 39. Global Dilated Cardiomyopathy Therapeutic: by Drug Class USD Million (2023-2028)
  • Figure 40. Global Dilated Cardiomyopathy Therapeutic: by End User USD Million (2023-2028)
  • Figure 41. South America Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 42. Asia Pacific Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 43. Europe Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 44. MEA Dilated Cardiomyopathy Therapeutic Share (%), by Country
  • Figure 45. North America Dilated Cardiomyopathy Therapeutic Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Zensun Shanghai Sci & Tech Co Ltd (China)
  • Capricor Therapeutics, Inc.(United States)
  • Vericel Corporation (United States)
  • AstraZeneca plc. (United Kingdom)
  • Pfizer Inc. (United States)
  • t2cure GmbH (Germany)
  • MyoKardia (United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Merck & Co., Inc. (United States)
  • Novartis International AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Vericel Corporation (United States)
Additional players considered in the study are as follows:
Array BioPharma, Inc.(United States) , Celladon Corporation (United States) , GlaxoSmithKline plc. (United Kingdom)
Select User Access Type

Key Highlights of Report


Dec 2023 241 Pages 85 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dilated Cardiomyopathy Therapeutic Market Quantitative research analysis
Global Dilated Cardiomyopathy Therapeutic Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Zensun Shanghai Sci & Tech Co Ltd (China), Capricor Therapeutics, Inc.(United States), Vericel Corporation (United States), AstraZeneca plc. (United Kingdom), Pfizer Inc. (United States), t2cure GmbH (Germany), MyoKardia (United States), Janssen Pharmaceuticals, Inc. (Belgium), Merck & Co., Inc. (United States), Novartis International AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel) and Vericel Corporation (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Incidence of Cardiovascular Diseases" is seen as one of major influencing trends for Dilated Cardiomyopathy Therapeutic Market during projected period 2022-2028.
The Dilated Cardiomyopathy Therapeutic market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dilated Cardiomyopathy Therapeutic Market Report?

Have a Query? Click Here

Other Related Reports

Skin Barrier Comprehensive Study by Shape (Flat, Convex), Surgery (Colostomy, Ileostomy, Urostomy) Players and Region - Global Market Outlook to 2026
$ 3500
Cachexia Treatment Comprehensive Study by Application (Cancer, Chronic Kidney Disease, Congestive Heart Failure (CHF), Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthri...
$ 3750
Anthrax Treatment Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Disease Type (Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax, Injectio...
$ 3750
Gynecomastia Treatment Comprehensive Study by Type (Surgery, Medication), Application (Hospitals, Clinics, Ambulatory Surgical Centres), Drug Type (Tamoxifen, Raloxifene, Aromatase Inhibitors, Others...
$ 3750
Cystic Fibrosis Therapeutic Comprehensive Study by Type (Medications, Airway Clearance Techniques, Pulmonary Rehabilitation, Surgery), Application (Hospitals, Homecare, Speciality Centres), Route of ...
$ 3750
Valvular Heart Diseases Treatment Comprehensive Study by Application (Congenital Heart Disease, Valve Stenosis, Valve Regurgitation, Others), Treatment (Surgery, Medication), Route of Administration ...
$ 3750